Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 107 - 145
Published: Nov. 8, 2024
Language: Английский
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7131 - 7131
Published: June 28, 2024
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Therefore, need for new therapeutic strategies still a challenge. Surgery and chemotherapy represent first-line interventions; nevertheless, prognosis metastatic CRC (mCRC) patients remains unacceptable. An important step towards targeted therapy came from inhibition epidermal growth factor receptor (EGFR) pathway, by anti-EGFR antibody, Cetuximab, or specific tyrosine kinase inhibitors (TKI). mouse-human chimeric monoclonal antibody (mAb), binds to extracellular domain EGFR thus impairing EGFR-mediated signaling reducing cell proliferation. TKI can affect biochemical pathway at different steps along cascade. Apart other mAbs have been developed, such as Panitumumab. Both antibodies approved treatment KRAS-NRAS wild type mCRC, alone in combination with chemotherapy. These display strong differences activating host immune system against CRC, due their immunoglobulin isotypes. Although are efficient, drug resistance occurs high frequency. Resistant tumor populations either already be present before develop later adaptations genomic mutations pathway. Numerous efforts made improve efficacy find agents that able block downstream cascade molecules. Indeed, we examined importance analyzing antibody-drug conjugates (ADC) developed overcome and/or stimulate host's immunity growth. Also, patient-derived organoid cultures useful feasible vitro model study behavior response. Organoids reflect genetic heterogeneity found tissue origin, representing unique tool personalized medicine. Thus, CRC-derived smart studying microenvironment preclinical assay drugs.
Language: Английский
Citations
5
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11535 - 11535
Published: Oct. 27, 2024
Biomarkers in colorectal cancer (CRC) are of great interest the current literature due to improvements techniques such as liquid biopsy and next-generation sequencing (NGS). However, screening methods vary globally, with multi-target stool DNA (mt-sDNA) predominantly used USA and, more recently, Cologuard Plus; biomarkers Galectins family septins show promise early detection. Gut microbiome assessments, Fusobacterium nucleatum, under intense exploration. Diagnostic tests, circulating analysis via NGS, exhibit effectiveness being increasingly adopted. Circulating tumor cells emerge potential alternatives traditional terms diagnosis prognosis. Predictive well established guidelines; nonetheless, aid machine learning artificial intelligence, these may be improved. This review critically explores actual dynamic landscape CRC future, promising involved screening, diagnosis,
Language: Английский
Citations
5
Journal of Gastrointestinal Cancer, Journal Year: 2025, Volume and Issue: 56(1)
Published: Jan. 23, 2025
Language: Английский
Citations
0
Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 927 - 927
Published: March 8, 2025
Introduction: Liquid biopsies provide a less-invasive option to tissue for the early diagnosis, prognosis, and tailored therapy of colorectal cancer (CRC). CRC is major cause cancer-related death, identification essential improving patient outcomes. Review: Conventional diagnostic techniques, including colonoscopy biopsy, may be enhanced by liquid that examine circulating tumor cells (CTCs), DNA (ctDNA), extracellular vesicles (EVs), other indicators present in body fluids. These markers significant insights into biology, heterogeneity, therapeutic response. CTCs detected early-stage have prognostic significance disease recurrence survival, while ctDNA investigation uncover genetic mutations, epigenetic alterations, development. The minimal residual (MRD) postsurgery correlates with an elevated risk unfavorable underscoring its use assessing treatment effectiveness. Furthermore, non-coding RNAs (ncRNAs) contained inside EVs potential prospective biomarkers targets, facilitating diagnosis assessment. Notwithstanding biopsies, obstacles persist assay standardization, sensitivity enhancement, management heterogeneity. Additional extensive research required determine their function clinical practice. Conclusion: Overall, serve as instrument real-time monitoring, evaluating responses, directing individualized strategies patients.
Language: Английский
Citations
0
Clinical and Translational Science, Journal Year: 2025, Volume and Issue: 18(3)
Published: March 1, 2025
ABSTRACT The use of a liquid biopsy to assess molecular residual disease (MRD) solid tumors holds significant promise for improving outcomes patients with cancer. Liquid biopsies are minimally invasive approach the identification circulating tumor biomarkers through simple blood sample. Assays capable detecting MRD analysis DNA (ctDNA) rapidly evolving clinical study applications and therapeutic interventions. To address these opportunities, BLOODPAC—a multi‐disciplinary consortium representing stakeholders from public, industry, academia, regulatory agencies—formulated lexicon that provides shared framework clear definitions using an emphasis on ctDNA detection. terms in categorized under general MRD, testing methodologies, reporting results, acquisition timepoints, including examples current potential cases tests. overall goal is provide unified language approaches advance technologies, allow data aggregation strengthen future evidence, facilitate approvals, leading as early endpoint trials. We believe common set terminology methods can improve understanding appropriate testing, accelerate development, cancer patients.
Language: Английский
Citations
0
ESMO Open, Journal Year: 2025, Volume and Issue: 10(5), P. 105079 - 105079
Published: May 1, 2025
Liquid biopsy has already proven effective in aiding diagnosis, risk stratification and treatment personalization several malignancies, it could represent a practice-changing tool also biliary tract cancer, even though clinical applications are currently still limited. It is promising for early especially high-risk populations, studies on circulating free DNA (cfDNA), tumour cells differential microRNA (miRNA) profiles this setting ongoing. Circulating (ctDNA) appears as feasible noninvasive biomarker the curative setting, detecting minimal residual disease after resection monitoring recurrence. As of today, can be particularly valuable cancer genomic profiling, with good concordance tissue samples most molecular alterations. CtDNA analysis may considered practice when not sufficient next-generation sequencing, or urgent therapeutic decisions needed. Moreover, offers possibility providing real-time picture to monitor response dynamically identify resistance mutations, potentially representing way optimize strategies.
Language: Английский
Citations
0
International Journal of Surgery, Journal Year: 2024, Volume and Issue: unknown
Published: March 25, 2024
Background: The application of liquid biopsy analysis utilizing circulating tumor DNA (ctDNA) has gained prominence as a biomarker in specific cancer types. Nevertheless, the correlation between ctDNA and prognostic outcomes patients with esophageal (EC) remains subject controversy. This meta-analysis aims to assess prognosis EC patients. Methods: We systematically explored Embase, PubMed, Cochrane Database identify studies reporting on value before November 2023. primary outcome involved determine associations overall survival (OS), disease-free (DFS)/recurrence-free (RFS), well asprogression-free (PFS) among Secondary encompassed detailed subgroup setting EC, including parameters such detection time, histological subtypes, treatment modalities, regions, anatomic locations, methods. Publication bias was assessed Begg’s test, Egger’s funnel plots. A sensitivity conducted by excluding individual evaluate stability results. Results: total 1203 were initially screened, from which 13 underwent further analysis, encompassing 604 diagnosed EC. comprehensive pooled indicated significant association poor OS (HR: 3.65; 95% CI: 1.97–6.75, P <0.001), DFS/RFS 6.08; 1.21–30.50, PFS 2.84; 1.94–4.16, <0.001). Subgroup showed that remained consistent negative predictor when stratified different Furthermore, regions study types demonstrated an Conclusion: Our results indicate plasma may serve robust markers for OS, DFS/RFS, finding suggests could offer highly effective approach risk stratification personalized medicine.
Language: Английский
Citations
3
Abdominal Radiology, Journal Year: 2024, Volume and Issue: 49(12), P. 4295 - 4306
Published: Aug. 8, 2024
Abstract Purpose Tumoral heterogeneity poses a challenge for personalized cancer treatments. Especially in metastasized cancer, it remains major limitation successful targeted therapy, often leading to drug resistance due tumoral escape mechanisms. This work explores non-invasive radiomics-based approach capture textural liver lesions and compare between colorectal (CRC) pancreatic (PDAC). Materials methods In this retrospective single-center study 73 subjects (42 CRC, 31 PDAC) with 1291 metastases (430 861 were segmented fully automated on contrast-enhanced CT images by UNet medical images. Radiomics features extracted using the Python package Pyradiomics. The mean coefficient of variation (CV) was calculated patient-wise each feature quantify heterogeneity. An unpaired t-test identified significant differences variability CRC PDAC metastases. Results both metastases, interlesional imaging can be observed quantitative features. 75 second-order varying characteristics. total, 18 radiomics showed difference ( p < 0.05) their expression two malignancies. Out these, 16 higher levels within cohort which, as illustrated radar plot, suggests greater entity. Conclusions has potential identify texture among individual proof-of-concept quantification comparison imaging-related extent shown.
Language: Английский
Citations
1
Biology, Journal Year: 2024, Volume and Issue: 13(12), P. 1007 - 1007
Published: Dec. 3, 2024
In 2022, colorectal cancer (CCR) had the second-highest incidence in Europe, preceded only by breast [...]
Language: Английский
Citations
1
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: May 8, 2024
Objective For liquid biopsy of cancer, the extraction circulating cell-free DNA (cfDNA) from plasma is required. We evaluated efficacy use magnetic submicron particles coated with abundant small zwitterions (MSP-ZEWBs) for extracting short fragments cfDNA. Methods developed and optimized an MSP-ZEWB-based cfDNA method using ampholytic ion-exchange materials compared its results those a control kit. measured concentration by quantitative polymerase-chain-reaction Qubit analyzed fragmentation patterns bioanalyzer. Results The fragment size isolated glycine hydrochloric acid at pH 2.2 exhibited better alignment marker. highest intensity was observed final 0.8% polyethylene glycol 8000. decreased significantly when marker MSP-ZEWBs adsorption buffer containing guanidine hydrochloride or isothiocyanoguanidine. All were successfully extracted both phosphate-buffered saline. Notably, remained consistent recovery long fragments. indicating potential selective Conclusion requires no protein denaturation, shows resistance to cells remaining in plasma, demonstrates higher overall efficiency reproducibility than other methods. Use may greatly enhance cancers through analysis clinical practice.
Language: Английский
Citations
0